Globe News Wire
01 Jun 2026, 09:32 UTC · 2h ago
Source · https://www.globenewswire.com/news-release/2026/06/01/3304114/0/en/aplagon-announces-review-publication-on-apac-a-first-in-class-dual-action-antithrombotic-to-treat-unmet-clinical-needs-in-thromboinflammatory-diseases.html
Read source
Search tags
Story key points
4 claims · impact-rated
Aplagon is currently conducting a Phase 2a clinical study for APAC targeting peripheral arterial occlusive disease (PAOD/CLTI) and planning a Phase 2 study for arteriovenous fistula (AVF) failure. — Progression into Phase 2 trials for a first-in-class drug is a major valuation driver for clinical-stage biotech companies.
+0.60Early clinical trials for APAC have demonstrated favorable safety and tolerability via both systemic and local administration. — Positive safety data reduces the risk of early-stage failure, increasing the probability of successful later-phase trials.
+0.40APAC is a first-in-class dual-action heparin proteoglycan mimetic that combines antiplatelet and anticoagulant activity in a single agent to reduce bleeding risks compared to standard-of-care combinations. — The potential to replace a multi-drug regimen with a single, safer agent creates a significant competitive advantage in a high-morbidity market.
+0.30Continue reading
6 related stories
A comprehensive review of APAC's preclinical and clinical evidence was published in the journal Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB). — Peer-reviewed publications provide scientific validation but are less market-moving than trial results or regulatory milestones.
+0.10Ticker attribution
Model heads
No ticker sentiment head found.
No ticker relationship head found.
Impact vectors
4 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
Benzinga
9h ago
